Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?

Affiliations

• ¹ Thoracic Oncology Department, Georges Pompidou European Hospital, Paris CARPEM Cancer Institute, AP-HP Centre, Université Paris Cité, Paris; INSERM Immunotherapy and Anti-Angiogenic Therapy in Oncology, PARCC, Paris.
• ² Faculty of Health, Sorbonne Université, Paris.
• ³ Drug Development Department (DITEP), Gustave Roussy, Paris-Saclay University, Villejuif; INSERM, U1015, Paris-Saclay University, Villejuif.
• ⁴ Paris Saclay University, AP-HP, Department of Internal Medicine and Clinical Immunology, Hôpital du Kremlin-Bicêtre, INSERM, CEA, UMR1184, Le Kremlin-Bicêtre, France. Electronic address: olivier.lambotte@aphp.fr.